- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01226342
Transcutaneous Electrical Muscle Stimulation In Chronic Obstructive Pulmonary Disease (COPD)
April 10, 2013 updated by: Mitja Lainščak, The University Clinic of Pulmonary and Allergic Diseases Golnik
Transcutaneous Electrical Muscle Stimulation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Transcutaneous electrical muscle stimulation (TCEMS) is well established intervention for rehabilitation of clinically stable patients with chronic obstructive pulmonary disease.
The investigators have conceived this study to test whether TCEMS is feasible and tolerated by patients experiencing severe physical and psychical challenge of acutely exacerbated COPD.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
19
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Golnik, Slovenia, SI-4204
- University Clinic Golnik
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- chronic obstructive pulmonary disease GOLD stage III or IV
- acute exacerbation of the disease
Exclusion Criteria:
- contraindications for transcutaneous electrical muscle stimulation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: TCEMS
Patients who will receive transcutaneous electrical muscle stimulation
|
On the first hospitalization day patients received lower extremity TCEMS.
We used GymnaUniphy device (GymnaUniphy N.V., 2004, 3740 Bilzen, Belgium) with four surface patch electrodes applied over each lower extremity quadriceps muscle.
Patients were in the supine position and were advised to relax during sessions.
A prespecified program for lower extremity strength training in sessions of 25 minutes, twice a day (first training in the morning, second in the afternoon, with minimal time difference of 6 hours) was performed six days per week during the hospitalization.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Scores on the feasibility scale
Time Frame: 10 days (avarage time from admission to discharge)
|
Patients will be followed from admission until discharge
|
10 days (avarage time from admission to discharge)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Scores on the patient satisfaction scale
Time Frame: 10 days (avarage time from admission to discharge)
|
Patients will be followed from admission until discharge
|
10 days (avarage time from admission to discharge)
|
|
Number of patients with adverse events as a measure of Safety and tolerability
Time Frame: 10 days (avarage time from admission to discharge)
|
Patients will be followed from admission until discharge
|
10 days (avarage time from admission to discharge)
|
|
Health related quality of life on the St. George respiratory questionnaire
Time Frame: 10 days (avarage time from admission to discharge)
|
Patients will be followed from admission until discharge
|
10 days (avarage time from admission to discharge)
|
|
Dyspnea on the MRC dyspnea scale
Time Frame: 10 days (avarage time from admission to discharge)
|
Patients will be followed from admission until discharge
|
10 days (avarage time from admission to discharge)
|
|
Patient symptom scores on the Functional assessment of chronic illness therapy questionaire
Time Frame: 10 days (avarage time from admission to discharge)
|
Patients will be followed from admission until discharge
|
10 days (avarage time from admission to discharge)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Mitja Lainscak, MD, PhD, University Clinic Golnik
- Study Chair: Mitja Kosnik, MD, PhD, contraindications for TCEMS
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
June 1, 2009
Study Completion (Actual)
October 1, 2009
Study Registration Dates
First Submitted
October 18, 2010
First Submitted That Met QC Criteria
October 21, 2010
First Posted (Estimate)
October 22, 2010
Study Record Updates
Last Update Posted (Estimate)
April 11, 2013
Last Update Submitted That Met QC Criteria
April 10, 2013
Last Verified
April 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Golnik-COPD-TENS-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.